Biologics for Chronic Rhinosinusitis with Nasal Polyps in France

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This French registry collects data on adults with chronic rhinosinusitis with nasal polyps who require biologic therapy. It tracks real-world outcomes from treatments already approved for CRSwNP, focusing on clinical and biological data since August 2021. The study aims to understand endotype-based patient responses and how biomarkers relate to treatment effectiveness, with retrospective data complemented by prospective follow-up. No randomized interventions are introduced; treatment decisions follow standard clinical practice under existing approvals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients of over 18-year old requiring a biologic treatment for CRswNP in accordance with its marketing approval.
* The patients already treated according to this criteria since August 2021 will be followed and their previous clinical and biological data retrospectively collected

Exclusion Criteria:

* Oral corticotherapy in the previous month;
* Biologic treatment with anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab, benralizumab) or anti-IL-4/IL-13R (dupilumab) or any other biotherapy for inflammatory diseases in the previous 6 months of initiation of treatment apart from ongoing biotherapies for severe asthma or CRSwNP;
* Hypersensitivity to humanized antibodies ;
* Documented SARS-Cov2 infection in the last 3 months with persistent olfactory disorders related to COVID;
* Pregnant or breast-feeding women;
* Patient without social coverage.

Where it's running

• chu de Lille
  Lille, France Recruiting
• CHU de Lille
  Lille, France Active not recruiting

Study contacts

• Study coordinator: Geoffrey Mortuaire, MD, pHD
• Email: geoffrey.mortuaire@chru-lille.fr
• Phone: 0320445675

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metabolic and Immunologic Biomarkers in Chronic Rhinosinusitis with Nasal Polyps

  This study tests whether metabolic and immune markers in nasal tissue and blood differ between people with nasal polyps and those without, to help understand CRSwNP and find potential diagnostic clues.

  Recruiting Harran University · Sanliurfa, Şanlıurfa · NCT07860411

• GSK5784283 as add-on therapy for chronic rhinosinusitis with nasal polyps

  This study tests whether GSK5784283 added to standard care can help adults with chronic rhinosinusitis with nasal polyps feel better and have fewer symptoms.

  Recruiting at 8 sites Phase 3 GlaxoSmithKline · Los Angeles, California and 7 other locations · NCT07782970

• GSK5784283 as add-on maintenance therapy for nasal polyps in chronic rhinosinusitis

  This study tests whether adding GSK5784283 (Felcorekibart) to standard care helps people with chronic rhinosinusitis with nasal polyps.

  Recruiting at 4 sites Phase 3 GlaxoSmithKline · Sherman Oaks, California and 3 other locations · NCT07782957

• Triamcinolone-loaded nanocapsules after endoscopic nasal surgery

  This trial tests whether a triamcinolone acetonide–loaded nanocapsule spray is better than saline irrigation for healing after endoscopic nasal surgery in adults with chronic rhinosinusitis and nasal polyps.

  Recruiting Phase 2 Deraya University · Minya, Menia Governorate · NCT07714525

• Depemokimab monotherapy for chronic rhinosinusitis with nasal polyps in Japanese adults

  This study tests depemokimab alone (without intranasal corticosteroids) in adults with chronic rhinosinusitis with nasal polyps in Japan.

  Recruiting at 10 sites Phase 4 GlaxoSmithKline · Ehime and 9 other locations · NCT07701967

• Stopping mepolizumab or dupilumab to see if nasal polyps stay in complete remission.

  This trial will test whether adults with well-controlled nasal polyps who have been on mepolizumab or dupilumab can safely stop the biologic and remain symptom-free.

  Recruiting at 6 sites Phase 4 Copenhagen University Hospital, Rigshospitalet · Copenhagen, Region H and 5 other locations · NCT07268313

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.